1-3 of 3
Lauren Saguilig
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

NPM::ALK Transcript Levels and Anti-ALK Autoantibody Titers As Biomarkers for Outcome in Pediatric ALK+ Anaplastic Large Cell Lymphoma Treated with Brentuximab Vedotin or Crizotinib in Combination with Chemotherapy: COG ANHL12P1

Christopher J. Forlenza, David Hoogstra, Donald Barkauskas, Lauren Saguilig, Suzanne D. Turner, Nina Prokoph, Perla Pucci, Lucy Hare, Leila Jahangiri, Rui Wu, Kojo S.J. Elenitoba-Johnson, Eric J. Lowe, Megan S. Lim
Journal: Blood
Blood (2024) 144 (Supplement 1): 1581.
https://doi.org/10.1182/blood-2024-201677
Published: 2024
Journal Articles

Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK + ALCL: results of COG trial ANHL12P1

Clinical Trials & Observations
Eric J. Lowe, Anne F. Reilly, Megan S. Lim, Thomas G. Gross, Lauren Saguilig, Donald A. Barkauskas, Rui Wu, Sarah Alexander, Catherine M. Bollard
Journal: Blood
Blood (2021) 137 (26): 3595–3603.
https://doi.org/10.1182/blood.2020009806
Published: 2021
Includes: Supplemental data
Journal Articles

Toxicity Profile of Brentuximab Vedotin in Combination with Chemotherapy for Newly Diagnosed Patients with ALK+ ALCL: A Children's Oncology Group Study ANHL12P1

Eric J Lowe, MD, Anne Reilly, MD, Catherine M. Bollard, MD, Donald A Barkauskas, Allen B Buxton, David Hall, Lauren Saguilig, John T. Sandlund, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1625.
https://doi.org/10.1182/blood-2018-99-118450
Published: 2018